Aryl furan derivatives as PDE IV inhibitors

A compound of Formula I ##STR63## or a pharmaceutically acceptable salt thereof wherein:

• Ar.sub.1 is an aromatic ring selected from phenyl, pyridinyl, or furyl, optionally substituted with up to two substituents, each substituent independently is:
• a) C.sub.1-6 alkyl, optionally substituted with --OH, --CO.sub.2 H, CO.sub.2 C.sub.1-3 alkyl, or CN,
• b) C.sub.1-6 alkoxy,
• c) C.sub.1-3 alkylthio,
• d) C.sub.1-3 alkylsulfonyl,
• e) C.sub.1-3 fluoroalkyl, optionally substituted with --OH,
• f) halo,
• g) --OH,
• h) --CO.sub.2 H, or
• i) --CO.sub.2 C.sub.1-3 alkyl;
• Ar.sup.2 is an aromatic ring selected from phenyl, benzothiazolyl, benzoxazolyl, pyrimidinyl, pyridinyl, purinyl or imidazolyl, optionally substituted with up to two substituents, each substituent independently is:
• 1) C.sub.1-6 alkyl,
• 2) C.sub.1-6 alkoxy,
• 3) --OH,
• 4) halo, or
• 5) CF.sub.3 ;
• R.sub.2 is
• a) hydrogen or
• b) C.sub.1-3 alkyl;
• and
• R.sub.3 is phenyl, pyridinyl, quinolinyl or furyl, optionally substituted with up to two substituents, each substituent independently is:
• a) C.sub.1-3 alkyl,
• b) C.sub.1-3 fluoroalkyl,
• c) C.sub.1-6 alkoxy,
• d) C.sub.1-3 fluoroalkoxy,
• e) C.sub.1-3 alkylthio,
• f) halo, or
• g) --OH.